Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Scrotal Pain, CTCAE 5.0	NCIT_C146665	[A disorder characterized by a sensation of marked discomfort in the scrotal area.]
C-SSRS Already Enrolled Subjects - Actual Suicide Attempt (Since Study Start)	NCIT_C107057	[Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died? (Since Study Start).]
AL Hagedoorn, Neth	NCIT_C15007
Testicular Pain, CTCAE 5.0	NCIT_C146666	[A disorder characterized by a sensation of marked discomfort in the testis.]
C-SSRS Already Enrolled Subjects - Number of Actual Suicide Attempts (Prior to Study Entry)	NCIT_C107058	[Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of actual attempts. (Prior to Study Entry).]
QC Mouse	NCIT_C15008
Yiqi-yangyin-jiedu Herbal Decoction	NCIT_C132026	[A traditional Chinese medicine (TCM) based formulation consisting of milkvetch root, glehnia root, asparagus root, lilyturf root, grossy privet fruit, spikemoss herb, Chinese sage herb, and manyleaf paris rhizome, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, yiqi-yangyin-jiedu decoction (YYJD) may activate the immune system by enhancing T-lymphocyte activity, and inhibiting tumor cell proliferation. YYJD may also ameliorate the qi-yin deficiency syndrome by strengthening qi and nourishing yin. YYJD may help remove toxic substance.]
C-SSRS Already Enrolled Subjects - Duration of Most Severe Ideation (Prior to Study Entry)	NCIT_C107048	[Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) When you have the thoughts, how long do they last? (Prior to Study Entry).]
Outbred Mice, Carworth Farms	NCIT_C15009
CD8+NKG2D+ AKT Cell	NCIT_C132027	[A preparation of human CD8-positive tumor-specific T-lymphocytes engineered to express the natural killer cell activating receptor group 2D (NKG2D) and the serine/threonine kinase AKT, with potential immunomodulating and antineoplastic activities. Upon administration of CD8+NKG2D+ AKT cells, these cells target and kill tumor cells. AKT-mediated signaling enhances the activation, differentiation, proliferation and cytokine production of tumor specific T-cells, which enhances their anti-tumor effects; AKT activity in T-cells is often downregulated in the tumor environment. NKG2D, a stimulatory lymphocyte receptor, mediates the recognition of tumors cells and promotes T-cell activation and T-cell-mediated tumor cell killing; NKG2D ligands are expressed on cancer cells, while they are minimally expressed by or absent from normal, healthy cells.]
C-SSRS Already Enrolled Subjects - Duration of Most Severe Ideation (Since Study Start)	NCIT_C107049	[Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) When you have the thoughts, how long do they last? (Since Study Start).]
PSMA-targeted PET Imaging Agent Fluorine F 18 CTT-1057	NCIT_C132028	[A radioconjugate composed of the phosphoramidate agent CTT1057, a human prostate specific membrane antigen (PSMA) inhibitor, and labeled with the radioisotope fluorine F 18, with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of PSMA-targeted PET imaging agent fluorine F 18 CTT-1057, the CTT-1057 moiety targets and irreversibly binds to the extracellular domain of PSMA-expressing tumor cells. Upon rapid internalization, and following PET imaging, PSMA-expressing tumor cells can be detected. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.]
Gallium Ga 68-NODAGA-Ac-Cys-ZEGFR:1907	NCIT_C132029	[A radiolabeled recombinant EGFR-specific affibody molecule composed of an epidermal growth factor receptor (EGFR)-targeting protein, the anti-EGFR affibody ZEGFR:1907 with an acetylated cysteine (Ac-Cys) at the N terminal of the affibody, and conjugated to the radioisotope gallium Ga 68, via the chelating agent NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid), with potential use for imaging EGFR-expressing tumor cells upon positron emission tomography (PET). Upon administration of gallium Ga 68-NODAGA-Ac-Cys-ZEGFR:1907, the ZEGFR:1907 affibody molecule moiety targets and binds to the extracellular domain (ECD) of EGFR expressed on various tumor cell types. Upon PET, EGFR-expressing tumor cells can be visualized. EGFR, frequently overexpressed in cancers, plays important roles in cell proliferation, survival, adhesion, migration, and differentiation. The affibody protein scaffold is based on the Z-domain, which is derived from one of the immunoglobulin (Ig) G-binding domains of staphylococcal protein A.]
BCL6 Gene Rearrangement	NCIT_C132020	[A molecular abnormality indicating rearrangement of the BCL6 gene.]
Rearrangement of 3q	NCIT_C79086
BCL6 Gene	NCIT_C24260	[This gene is involved in transcriptional repression and plays a role in the modulation of B-cell responses.]
BCL2 Gene Amplification	NCIT_C132021	[A molecular genetic abnormality indicating the presence of multiple copies of the BCL2 gene.]
BCL6 Gene Amplification	NCIT_C132022	[A molecular genetic abnormality indicating the presence of multiple copies of the BCL6 gene.]
EGFR Mutant-specific Inhibitor CK-101	NCIT_C132023	[An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, and the L858R and del 19 mutations, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor CK-101 specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, CK-101 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.]
Yang Yin Fu Zheng	NCIT_C132024	[A traditional Chinese medicine (TCM)-based formulation, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, Yang Yin Fu Zheng may activate the immune system and may help inhibit tumor cell proliferation. This TCM may also help remove toxic substances.]